

## Peptide Arrays, Control Peptides for MHC Class I & II Epitopes of Influenza Virus A & B Proteins

### Catalog No. NR-2666

This reagent is the tangible property of the U.S. Government.

### For research use only. Not for human use.

#### Contributor:

BEI Resources

#### Manufacturer:

CS Bio Company Inc.

#### Product Description:

NR-2666 contains seven peptide arrays. The first peptide array (NRC-244; 35 peptides) consists of Major Histocompatibility Complex (MHC) Class I epitopes of the HA (H1), NA (N1), NP, M1, M2, NS1, PA and PB1 proteins of influenza A virus.<sup>1</sup> The second peptide array (NRC-245; 9 peptides) consists of MHC Class II epitopes of the HA (H3), NP, M1 and NS1 proteins of influenza A virus.<sup>1</sup> The third peptide array (NRC-331; 1 peptide) consists of an MHC Class II epitope of the HA protein of influenza virus A/New Caledonia/20/1999 (H1N1) (GenPept: CAC86622).<sup>1,2</sup> The fourth peptide array (NRC-332; 1 peptide) consists of an MHC Class II epitope of the HA protein of influenza virus A/New York/384/2005 (H3N2) (GenPept: AAZ79974).<sup>1,3</sup> The fifth peptide array (NRC-333; 1 peptide) consists of an MHC Class II epitope of the HA protein of influenza virus A/Thailand/4(SP-528)/2004 (H5N1) (GenPept: AAV34704).<sup>1,4</sup> The sixth peptide array (NRC-246; 3 peptides) consists of MHC Class I epitopes of the NP protein of influenza B virus.<sup>1</sup> The seventh peptide array (NRC-247; 1 peptide) consists of an MHC Class II epitope of the HA protein of influenza B virus.<sup>1</sup> Peptides are 8- to 16-mers. Please see Table 1 for length and sequence of individual peptides.

#### Material Provided:

Peptides are provided lyophilized at 1 mg per vial.

#### Packaging/Storage:

Lyophilized peptides should be placed in a closed dry environment with desiccants and stored at -20°C or colder immediately upon arrival. A frost-free freezer should be avoided, since changes in moisture and temperature may affect peptide stability.

#### Solubility:

Solubility may vary based on the amino acid content of the individual peptide (see Table 2). Peptides can almost always be dissolved in 100% DMSO.

#### Reconstitution:

Lyophilized peptides should be warmed to room temperature for 1 hour prior to reconstitution. They should be dissolved at the highest possible concentration, and then diluted with water or buffer to the working concentration. Buffer should be added only after the peptide is completely in solution because salts may cause aggregation.

The most common dissolution process is 1 mg of peptide in 1 mL of sterile, distilled water or 1 mL of 100% DMSO. The DMSO can be slowly diluted to a lower concentration with aqueous medium. Care must be taken to ensure that the peptide does not begin to precipitate out of solution. For cell-based assays, 0.5% DMSO in medium is usually well-tolerated.

Sonication and/or the addition of small amounts of dilute (10%) aqueous acetic acid for basic peptides, aqueous ammonia for acidic peptides or acetonitrile may also help dissolution (see Table 2). These solvents may not be appropriate for certain applications, including cell-based assays.

#### Storage of Reconstituted Peptides:

The shelf life of peptides in solution is very limited, especially for sequences containing cysteine, methionine, tryptophan, asparagine, glutamine, and N-terminal glutamic acid. In general, peptides may be aliquoted and stored in solution for a few days at -20°C or colder. For long-term storage, peptides should be re-lyophilized and stored at -20°C or colder. If long-term storage in solution is unavoidable, peptide solutions should be buffered to pH 5–6, aliquoted and stored at -20°C or colder. Freeze-thaw cycles should be avoided.

#### Citation:

Acknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Peptide Arrays, Control Peptides for MHC Class I & II Epitopes of Influenza Virus A & B Proteins, NR-2666.”

#### Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see [www.cdc.gov/biosafety/publications/bmb15/index.htm](http://www.cdc.gov/biosafety/publications/bmb15/index.htm).

#### Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.beiresources.org](http://www.beiresources.org). While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

**Use Restrictions:**

**This material is distributed for internal research, non-commercial purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as

performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale. This material may be subject to third party patent rights.

**References:**

1. Epstein, S. L., et al. "Cell-Mediated Immunity to Influenza." *Textbook of Influenza*. Eds. Nicholson, K., et al. London: Blackwell Science; 1998. Chapter 24.
2. Marozin, S., et al. "Antigenic and Genetic Diversity among Swine Influenza A H1N1 and H1N2 Viruses in Europe." *J. Gen. Virol.* 83 (2002): 735–745. PubMed: 11907321. GenPept: CAC86622.
3. Ghedin, E., et al. "The NIAID Influenza Genome Sequencing Project." Direct submission (2005). GenPept: AAZ79974.
4. Puthavathana, P., et al. "Molecular Characterization of the Complete Genome of Human Influenza H5N1 Virus Isolates from Thailand." *J. Gen. Virol.* 86 (2005): 423–433. PubMed: 15659762. GenPept: AAV34704.

ATCC® is a trademark of the American Type Culture Collection.



Table 1			
Peptide	Length	Protein	Sequence
<b>NRC-244: Influenza Virus A MHC Class I Peptides</b>			
1 of 35	9	HA (H1)	63-GIAPLQLGK-71
2 of 35	10	HA (H1)	149-VTAACSHAGK-158
3 of 35	11	HA (H1)	450-RTLDFHDSNVK-460
4 of 35	10	NA (N1)	75-SLCPIRGWAI-84
5 of 35	9	NA (N1)	213-CVNGSCFTV-221
6 of 35	9	NP	44-CTELKLSDY-52
7 of 35	9	NP	91-KTGGPIYKR-99
8 of 35	9	NP	146-TTYQRTRAL-154
9 of 35	11	NP	174-RRSGAAGAAVK-184
10 of 35	11	NP	188-TMVMELVRMIK-198
11 of 35	9	NP	265-ILRGSVAHK-273
12 of 35	9	NP	338-FEDLRVLSF-346
13 of 35	9	NP	339-EDLRVLSFI-347
14 of 35	9	NP	379-LELRSRYWA-387
15 of 35	9	NP	380-ELRSRYWAI-388

Table 1			
Peptide	Length	Protein	Sequence
<b>NRC-244: Influenza Virus A MHC Class I Peptides</b>			
16 of 35	8	NP	381-LRSRYWAI-388
17 of 35	9	NP	383-SRYWAIRTR-391
18 of 35	9	NP	418-LPFDRTTVM-426
19 of 35	9	NP	418-LPFDKPTIM-426
20 of 35	9	NP	418-LPFDKSTIM-426
21 of 35	9	NP	418-LPFEKSTVM-426
22 of 35	10	NP	470-KATSPIVPSL-479
23 of 35	9	M1	13-SIIPSGPLK-21
24 of 35	9	M1	51-ILSPLTKGI-59
25 of 35	9	M1	58-GILGFVFTL-66
26 of 35	10	M1	59-ILGFVFTLTV-68
27 of 35	8	M1	128-ASCMGLIY-135
28 of 35	9	M2	7-VETPIRNEW-15
29 of 35	10	M2	85-DADDSHFVSI-94
30 of 35	9	NS1	122-AIMDKNIL-130
31 of 35	9	NS1	158-GEISPLPSL-166
32 of 35	9	PA	46-FMYSDFHFI-54
33 of 35	9	PA	225-SLENFRAYV-233
34 of 35	9	PB1	413-NMLSTVLGV-421
35 of 35	9	PB1	591-VSDGGPNLY-599
<b>NRC-245: Influenza Virus A MHC Class II Peptides</b>			
1 of 9	16	HA (H3)	271-RGYFKMRTGKSSIMRS-286
2 of 9	12	HA (H3)	322-PKYVKQNTLKLA-333
3 of 9	13	HA (H3)	322-PKYVKQNTLKLAT-334
4 of 9	19	HA (H3)	322-PKYVKQNTLKLATGMRNVP-340
5 of 9	15	NP	365-IASNENMDAMESSTL-379
6 of 9	12	M1	18-GPLKAEIAQRLE-29
7 of 9	10	M1	234-LENLQAYQKR-243
8 of 9	12	M1	239-AYQKRMGVQMQR-250
9 of 9	9	NS1	34-DRLRRDQKS-42
<b>NRC-331: Influenza Virus A/New Caledonia/20/99(H1N1) MHC Class II Peptide</b>			
1 of 1	13	HA (H1)	320-PKYVRSALRMVT-332
<b>NRC-332: Influenza Virus A/New York/384/2005(H3N2) MHC Class II Peptide</b>			
1 of 1	13	HA (H3)	322-PRYVKQNTLKLAT-334
<b>NRC-333: Influenza Virus A/Thailand/4(SP-528)/2004(H5N1) MHC Class II Peptide</b>			
1 of 1	13	HA (H5)	319-PKYVKSRLVLAT-331
<b>NRC-246: Influenza Virus B MHC Class I Peptides</b>			
1 of 3	9	NP	30-RPIIRPATL-38
2 of 3	10	NP	85-KLGEFYNQMM-94
3 of 3	9	NP	263-ADRGLLRDI-271
<b>NRC-247: Influenza Virus B MHC Class II Peptide</b>			
1 of 1	13	HA	308-PYYTGEHAKAIGN-320

Table 2			
Peptide	Solubility	Protein	Solvent
<b>NRC-244: Influenza Virus A MHC Class I Peptides</b>			
1 of 35	1 mg/mL	HA (H1)	25% acetonitrile in water
2 of 35	1 mg/mL	HA (H1)	25% acetonitrile in water
3 of 35	1 mg/mL	HA (H1)	25% acetonitrile in water
4 of 35	1 mg/mL	NA (N1)	25% acetonitrile in water
5 of 35	1 mg/mL	NA (N1)	25% acetonitrile in water
6 of 35	1 mg/mL	NP	25% acetonitrile in water
7 of 35	1 mg/mL	NP	25% acetonitrile in water
8 of 35	1 mg/mL	NP	25% acetonitrile in water
9 of 35	1 mg/mL	NP	25% acetonitrile in water
10 of 35	1 mg/mL	NP	25% acetonitrile in water
11 of 35	1 mg/mL	NP	25% acetonitrile in water
12 of 35	1 mg/mL	NP	50% acetonitrile in water
13 of 35	1 mg/mL	NP	25% acetonitrile in water
14 of 35	1 mg/mL	NP	25% acetonitrile in water
15 of 35	1 mg/mL	NP	25% acetonitrile in water
16 of 35	1 mg/mL	NP	25% acetonitrile in water
17 of 35	1 mg/mL	NP	25% acetonitrile in water
18 of 35	1 mg/mL	NP	25% acetonitrile in water
19 of 35	1 mg/mL	NP	25% acetonitrile in water
20 of 35	1 mg/mL	NP	25% acetonitrile in water
21 of 35	1 mg/mL	NP	25% acetonitrile in water
22 of 35	1 mg/mL	NP	25% acetonitrile in water
23 of 35	1 mg/mL	M1	25% acetonitrile in water
24 of 35	1 mg/mL	M1	25% acetonitrile in water
25 of 35	1 mg/mL	M1	25% acetonitrile in water
26 of 35	1 mg/mL	M1	50% acetonitrile in water
27 of 35	1 mg/mL	M1	25% acetonitrile in water
28 of 35	1 mg/mL	M2	25% acetonitrile in water
29 of 35	1 mg/mL	M2	25% acetonitrile in water
30 of 35	1 mg/mL	NS1	25% acetonitrile in water
31 of 35	1 mg/mL	NS1	25% acetonitrile in water
32 of 35	1 mg/mL	PA	25% acetonitrile in water
33 of 35	1 mg/mL	PA	25% acetonitrile in water
34 of 35	1 mg/mL	PB1	25% acetonitrile in water
35 of 35	1 mg/mL	PB1	25% acetonitrile in water

Table 2			
Peptide	Solubility	Protein	Solvent
<b>NRC-245: Influenza Virus A MHC Class II Peptides</b>			
1 of 9	1 mg/mL	HA (H3)	25% acetonitrile in water
2 of 9	1 mg/mL	HA (H3)	25% acetonitrile in water
3 of 9	1 mg/mL	HA (H3)	25% acetonitrile in water
4 of 9	1 mg/mL	HA (H3)	25% acetonitrile in water
5 of 9	1 mg/mL	NP	25% acetonitrile in water
6 of 9	1 mg/mL	M1	25% acetonitrile in water
7 of 9	1 mg/mL	M1	25% acetonitrile in water
8 of 9	1 mg/mL	M1	25% acetonitrile in water
9 of 9	1 mg/mL	NS1	25% acetonitrile in water
<b>NRC-331: Influenza Virus A/New Caledonia/20/99(H1N1) MHC Class II Peptide</b>			
1 of 1	1 mg/mL	HA (H1)	25% acetonitrile in water
<b>NRC-332: Influenza Virus A/New York/384/2005(H3N2) MHC Class II Peptide</b>			
1 of 1	1 mg/mL	HA (H3)	25% acetonitrile in water
<b>NRC-333: Influenza Virus A/Thailand/4(SP-528)/2004(H5N1) MHC Class II Peptide</b>			
1 of 1	1 mg/mL	HA (H5)	25% acetonitrile in water
<b>NRC-246: Influenza Virus B MHC Class I Peptides</b>			
1 of 3	1 mg/mL	NP	25% acetonitrile in water
2 of 3	1 mg/mL	NP	25% acetonitrile in water
3 of 3	1 mg/mL	NP	25% acetonitrile in water
<b>NRC-247: Influenza Virus B MHC Class II Peptide</b>			
1 of 1	1 mg/mL	HA	25% acetonitrile in water